Archives: Agenda
Chairperson’s opening remarks
TITLE TBC
Interactive Speaker-Hosted Roundtable Discussions
Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within oncology clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.
After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.
| Roundtable 1 | Balancing quality, speed and cost in complex oncology trials
Umar Hayat Ph.D., Founder, CEO, Accanito Therapeutics Inc |
| Roundtable 2 | Is AI overhyped? Understanding how to incorporate AI to enhance trial processes
Radha Duttagupta, Vice President, Clinical Affairs, Nucleix |
| Roundtable 3 | Leveraging strong academic networks for complex oncology trials to assist in research and drug development
Irene Acerbi Soto, Clinical Implementations & Operations Manager, University of California San Francisco |
| Roundtable 4 | Tissue is the Issue: How to overcome limited oncologic samples to achieve clinical trial success
Osama Khan MD, FCAP, FRCPC, Anatomical Pathologist, Oncology, Natera |
Considered approaches to streamlining oncology clinical trial design to reduce patient burden
- Identifying protocol design elements that unintentionally increase patient burden in oncology trials
- Simplifying eligibility criteria without compromising scientific rigor
- Incorporating patient feedback into trial design to improve participation experience
- Considering recruitment and retention aspects
Afternoon refreshments and networking
Fine-tuning biomarker selection to enhance oncology drug development
- Enhancing biomarker selection to speed up oncology trial timelines
- Road mapping how to identify effective biomarkers to enhance oncology clinical trials
- Understanding regulatory considerations surrounding biomarker qualification